[go: up one dir, main page]

NO983147L - Anvendelse av en antagonist av PPAR-<alfa> og PPAR-<gamma> for behandling av syndrom X - Google Patents

Anvendelse av en antagonist av PPAR-<alfa> og PPAR-<gamma> for behandling av syndrom X

Info

Publication number
NO983147L
NO983147L NO983147A NO983147A NO983147L NO 983147 L NO983147 L NO 983147L NO 983147 A NO983147 A NO 983147A NO 983147 A NO983147 A NO 983147A NO 983147 L NO983147 L NO 983147L
Authority
NO
Norway
Prior art keywords
ppar
alfa
antagonist
syndrome
gamma
Prior art date
Application number
NO983147A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO983147L publication Critical patent/NO983147L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO983147A 1996-01-09 1998-07-08 Anvendelse av en antagonist av PPAR-<alfa> og PPAR-<gamma> for behandling av syndrom X NO983147L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9600464.3A GB9600464D0 (en) 1996-01-09 1996-01-09 Novel method
PCT/EP1997/000058 WO1997025042A1 (en) 1996-01-09 1997-01-07 Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x

Publications (1)

Publication Number Publication Date
NO983147L true NO983147L (no) 1998-09-08

Family

ID=10786844

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983147A NO983147L (no) 1996-01-09 1998-07-08 Anvendelse av en antagonist av PPAR-<alfa> og PPAR-<gamma> for behandling av syndrom X

Country Status (25)

Country Link
US (1) US6166049A (no)
EP (1) EP0879053A1 (no)
JP (1) JP2000503643A (no)
KR (1) KR19990077099A (no)
CN (1) CN1212622A (no)
AP (1) AP9801272A0 (no)
AR (1) AR005404A1 (no)
AU (1) AU1439797A (no)
BG (1) BG102668A (no)
BR (1) BR9706968A (no)
CA (1) CA2242632A1 (no)
CZ (1) CZ216398A3 (no)
EA (1) EA199800626A1 (no)
GB (1) GB9600464D0 (no)
HU (1) HUP9900560A3 (no)
IL (1) IL125106A0 (no)
MX (1) MX9805539A (no)
NO (1) NO983147L (no)
NZ (1) NZ502966A (no)
OA (1) OA10710A (no)
PL (1) PL327731A1 (no)
SK (1) SK92598A3 (no)
TR (1) TR199801315T2 (no)
WO (1) WO1997025042A1 (no)
ZA (1) ZA97171B (no)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
AU752059B2 (en) 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
US6265401B1 (en) 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
AU749505B2 (en) * 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
AU766831B2 (en) 1998-05-11 2003-10-23 Takeda Pharmaceutical Company Limited Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
EP1123269A1 (en) * 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
AU6325599A (en) * 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
US6365586B1 (en) 1998-10-21 2002-04-02 Novo Nordisk A/S Compounds, their preparation and use
WO2000023416A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023425A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6214820B1 (en) 1998-10-21 2001-04-10 Novo Nordisk A/S Compounds, their preparation and use
US6300339B1 (en) 1998-10-21 2001-10-09 Novo Nordisk A/S Compounds, their preparation and use
EP1123297A1 (en) * 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
US6468996B1 (en) 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
US6353018B1 (en) 1998-10-21 2002-03-05 Novo Nordisk A/S Compounds, their preparation and use
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
EP1171431A1 (en) * 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
WO2000063209A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
PL351312A1 (en) * 1999-04-20 2003-04-07 Novo Nordisk As New compounds, their preparation and use
US7414128B2 (en) 1999-04-20 2008-08-19 Dr. Reddy's Laboratories, Limited Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
CZ20013832A3 (cs) * 1999-04-28 2002-04-17 Dr. Reddy's Research Foundation Substituované bicyklické heterocyklické sloučeniny, způsob jejich přípravy a jejich pouľití jako antiobezitních a hypocholesterolemických činidel
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
US7323496B2 (en) 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6525093B1 (en) * 1999-11-08 2003-02-25 Calyx Therapeutics Inc. Compounds to treat diabetes and associated conditions
CZ304346B6 (cs) * 2000-01-19 2014-03-19 Cadila Healthcare Ltd. Substituovaný pyrrolový derivát s hypolipidemickou hypocholesteremickou aktivitou, způsob jeho přípravy a farmaceutický přípravek obsahující tyto sloučeniny
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
IL150259A0 (en) * 2000-01-28 2002-12-01 Novo Nordisk As Alkylnyl-substituted propionic acid derivatives and their use against diabetes and obesity
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
EP1348698A4 (en) 2000-12-05 2005-01-19 Kyorin Seiyaku Kk SUBSTITUTED CARBOXYLENE DERIVATIVES
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20040025890A (ko) * 2001-01-26 2004-03-26 쉐링 코포레이션 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와 혈액조절제의 조합물
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1355644T1 (sl) 2001-01-26 2006-10-31 Schering Corp Uporaba substituiranih azetidinonskih spojin za zdravljenje sitosterolemije
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
ATE369851T1 (de) * 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
BR0206644A (pt) * 2001-01-26 2004-02-25 Schering Corp Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
FR2822955B1 (fr) * 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
NZ529033A (en) 2001-05-15 2005-06-24 F Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
US20030013699A1 (en) * 2001-05-25 2003-01-16 Davis Harry R. Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DK1429756T3 (da) * 2001-09-21 2007-03-19 Schering Corp Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7319104B2 (en) 2002-03-01 2008-01-15 Smithkline Beecham Corporation hPPARs activators
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2003088962A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
ATE372990T1 (de) 2002-07-03 2007-09-15 Hoffmann La Roche Oxazolderivat und deren verwendung als insulinsensibilisatoren
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
BR0313946A (pt) 2002-08-30 2005-07-12 Hoffmann La Roche Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método
RU2296759C2 (ru) 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
ES2312819T3 (es) 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
US6653334B1 (en) 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
AU2004231554A1 (en) * 2003-04-17 2004-11-04 Kalypsys, Inc. (3-{3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino!-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
WO2004110357A2 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
CN101014595A (zh) * 2004-08-11 2007-08-08 杏林制药株式会社 新型环状氨基苯甲酸衍生物
DK1805158T3 (en) 2004-10-29 2018-08-06 Kalypsys Inc SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
WO2006082495A1 (en) * 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Peroxisome proliferator activated receptor modulators
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
EP1940815B1 (en) 2005-10-25 2018-08-15 Kalypsys, Inc. Salts of modulators of ppar and methods of treating metabolic disorders
RU2449999C2 (ru) 2006-01-18 2012-05-10 Эвольва Са Модуляторы ppar
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
AU2008206050B2 (en) 2007-01-18 2014-08-14 Evolva Sa Prodrugs of substituted 1,3-dioxanes and their uses
WO2008089464A1 (en) 2007-01-18 2008-07-24 Evolva Sa Prodrugs of substituted 1,3-dioxanes and their uses
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
US8754127B2 (en) 2009-02-16 2014-06-17 Nogra Pharma Limited Alkylamido compounds and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR101733414B1 (ko) 2011-01-31 2017-05-10 카딜라 핼쓰캐어 리미티드 지방이상증의 치료
CN104254327A (zh) 2012-02-09 2014-12-31 诺格拉制药有限公司 治疗纤维化的方法
BR112014026160A2 (pt) 2012-04-18 2017-07-18 Nogra Pharma Ltd métodos para tratar intolerância à lactose
WO2014174524A1 (en) 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (no) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
MX382765B (es) 2016-12-09 2025-03-13 Zydus Lifesciences Ltd Tratamiento para la colangitis biliar primaria.
UA129325C2 (uk) 2019-02-08 2025-03-19 Ногра Фарма Лімітед Спосіб одержання 3-(4'-амінофеніл)-2-метоксипропіонової кислоти, її аналогів і проміжних сполук

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA885473B (en) * 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
KR950702545A (ko) * 1992-07-03 1995-07-29 데이빗 로버츠 약제로서의 헤테로시클릭 화합물(Heterocyclic compounds as pharmaceutical)
WO1996004261A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
HUP9900560A3 (en) 2001-04-28
EA199800626A1 (ru) 1998-12-24
BR9706968A (pt) 1999-04-06
GB9600464D0 (en) 1996-03-13
TR199801315T2 (xx) 1998-10-21
CZ216398A3 (cs) 1999-02-17
JP2000503643A (ja) 2000-03-28
BG102668A (en) 1999-04-30
PL327731A1 (en) 1998-12-21
AP9801272A0 (en) 1998-06-30
US6166049A (en) 2000-12-26
EP0879053A1 (en) 1998-11-25
AU1439797A (en) 1997-08-01
SK92598A3 (en) 1999-01-11
IL125106A0 (en) 1999-01-26
AR005404A1 (es) 1999-04-28
ZA97171B (en) 1998-07-24
OA10710A (en) 2002-11-28
WO1997025042A1 (en) 1997-07-17
CA2242632A1 (en) 1997-07-17
HUP9900560A2 (hu) 1999-07-28
WO1997025042A8 (en) 2000-07-20
NZ502966A (en) 2001-11-30
KR19990077099A (ko) 1999-10-25
MX9805539A (es) 1998-11-29
CN1212622A (zh) 1999-03-31

Similar Documents

Publication Publication Date Title
NO983147L (no) Anvendelse av en antagonist av PPAR-&lt;alfa&gt; og PPAR-&lt;gamma&gt; for behandling av syndrom X
NO20006178D0 (no) Anvendelse av PEG-IFN-&lt;alfa&gt; og ribavirin for behandling av kronisk hepatitt C
NO984094D0 (no) Utladningsreaktor og anvendelse av samme
FI944259L (fi) Käytettävyysprosessori ja -menetelmä
IS4481A (is) Díhýdrópyramídín og notkun þeirra
IS6411A (is) Kaspasa tálmar og notkun þeirra
DE69404414D1 (de) Reinigungsverfahren und Reinigungsgerät
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
NO984354D0 (no) Avisingsmiddel og anvendelse av dette
NO990296D0 (no) HPPD-genet og inhibitorer
NO20003488D0 (no) Homopolymerer og kopolymerer av etylen
DK0804078T3 (da) Sammensætning og anvendelse deraf
DK0906301T3 (da) Benzofurylderivater og anvendelsen deraf
NO973714D0 (no) Innretning og dens anvendelse for oksyklorering
IT1277461B1 (it) Procedimento e dispositivo per il trattamento di materiali
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
NO984836L (no) Substituerte benzylaminer og deres anvendelse for behandling av depresjon
NO20011537D0 (no) Kjemokinreseptorpeptidvaksiner for behandling og forebygging av diabetes
NO983238D0 (no) Exodus kjemokin materialer og fremgangsmater
IS4312A (is) Skvalen lígasa efnahemlar og notkun theirra
PT1194038E (pt) Composicao de quebra do repouso e sua utilizacao
DK116692D0 (da) Method for the securing of an electro-acoustic device and electro-acoustic device for use in the method
FI964809A0 (fi) En utrustning foer tillverkning av taeckplaot
NO985068L (no) Vaksiner for behandling av lymfom og leukemi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application